What is TG Therapeutics's operating lease liabilities (total)?

TG Therapeutics (TGTX) reported operating lease liabilities (total) of $8.42M in Q1 2026.

How has TG Therapeutics's operating lease liabilities (total) changed year-over-year?

TG Therapeutics's operating lease liabilities (total) decreased by 6.2% year-over-year, from $8.98M to $8.42M.

What is the long-term trend for TG Therapeutics's operating lease liabilities (total)?

Over 5 years (2020 to 2025), TG Therapeutics's operating lease liabilities (total) has grown at a -7.8% compound annual growth rate (CAGR), from $12.08M to $8.07M.

TG Therapeutics TGTX Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

BridgeBio PharmaBBIO

$18.66M+84.3%

Krystal Biotech, Inc.KRYS

$9.11M-5.7%

Arrowhead ResearchARWR

$107.88M-5.6%

Roivant SciencesROIV

$107.44M+7.3%

Neurocrine BiosciencesNBIX

$463.5M-6.0%

Axsome TherapeuticsAXSM

$23.01M-5.5%

Other financials

Income statement

See full

Revenue$204.9M+69.6%

Gross profit$171.4M+62.8%

Operating income$34.8M+304%

Net income$19.8M+291%

EPS (diluted)$0.12+300%

Balance sheet

See full

Cash & equivalents$442.2M+235%

Total debt$753.6M+197%

Total equity$583.1M+146%

Total assets$1.5B+133%

Cash flow

See full

Operating cash flow-$17.9M+37.7%

CapEx$51.0K+104%

Free cash flow-$17.9M+37.6%

Valuation

See full

Market cap$8.15B-14.3%

Enterprise value$8.46B-11.1%

P/E17.6×-225×

P/S11.6×-13.0×

Profitability

See full

Gross margin83.1%-4.4pp

Operating margin21.3%+5.9pp

Net margin66%+55.8pp

FCF margin-6,328.4%+4,773pp

Returns & leverage

See full

Return on equity112.6%+92.9pp

Debt / equity1.3×+0.2×

Current ratio5.8×+1.8×

Where this comes from

Reported directly by TG Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.

The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about TG Therapeutics's operating lease liabilities (total).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is TG Therapeutics's operating lease liabilities (total)?: TG Therapeutics (TGTX) reported operating lease liabilities (total) of $8.42M in Q1 2026.
How has TG Therapeutics's operating lease liabilities (total) changed year-over-year?: TG Therapeutics's operating lease liabilities (total) decreased by 6.2% year-over-year, from $8.98M to $8.42M.
What is the long-term trend for TG Therapeutics's operating lease liabilities (total)?: Over 5 years (2020 to 2025), TG Therapeutics's operating lease liabilities (total) has grown at a -7.8% compound annual growth rate (CAGR), from $12.08M to $8.07M.